Every 10-Q that Anixa Biosciences, Inc. (ANIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIX filings page.
Anixa Biosciences, Inc. (ANIX) reported another development-stage quarter for the period ended July 31, 2026, with no revenue and a net loss attributable to common shareholders of $2.6 million for the quarter and $7.7 million for the nine months. Total operating expenses for the nine months were $8.1 million, down modestly from $8.8 million a year earlier, as research and development and general and administrative costs both declined, largely from lower stock-based compensation.
Total assets were $15.1 million, including $13.9 million in cash, cash equivalents and short-term investments, compared with $15.2 million at October 31, 2025. Net cash used in operating activities was $6.1 million for the nine months, partly offset by $4.8 million raised via an at-the-market equity offering. Anixa states that existing cash, cash equivalents and short-term investments are expected to fund operations for at least the next twelve months and for significantly longer than 12 months under its current plans.
Operationally, the company continues advancing its CAR-T ovarian cancer therapy and breast and ovarian cancer vaccine programs, with a Phase 1 CAR-T trial treating higher-dose cohorts and a completed Phase 1 breast cancer vaccine trial showing met primary endpoints and observed immune responses. Preparation is under way for a Phase 2 breast cancer vaccine trial.
Anixa Biosciences reported its quarterly results for the period ended April 30, 2026, remaining a pre-revenue biotech focused on cancer vaccines and CAR‑T therapies. The company posted a net loss attributable to common shareholders of $2.5 million for the quarter and $5.1 million for the six-month period, both modestly improved from the prior year as research and general expenses declined.
Anixa ended April 30, 2026 with $13.7 million in cash, cash equivalents and short‑term investments, down from $15.2 million at October 31, 2025, and believes this will fund operations for at least 12 months. During the six months, it raised $2.9 million via an at‑the‑market stock offering and maintains capacity to sell about $97 million more. The company continues a Phase 1 ovarian cancer CAR‑T trial showing good tolerability with anecdotal signs of efficacy, and completed Phase 1 of its breast cancer vaccine with all primary endpoints met and immune responses in 74% of subjects, preparing now for Phase 2.
Anixa Biosciences reported quarterly results for the three months ended January 31, 2026, showing a net loss attributable to common shareholders of $2.565M, improved from $3.184M a year earlier. The company generated no revenue, reflecting its focus on developing cancer vaccines and CAR-T therapies.
Research and development expenses fell to $1.102M and general and administrative expenses to $1.614M, both down from the prior year as certain trial and manufacturing activities tapered. Cash, cash equivalents and short-term investments totaled $14.202M at January 31, 2026, after raising $1.625M through an at-the-market stock offering.
The CAR-T program for ovarian cancer has treated 13 patients in a dose-escalation Phase 1 trial, with treatment reported as well-tolerated across cohorts and several patients living well beyond typical median survival, though the study is primarily designed to assess safety. Anixa’s breast cancer vaccine completed Phase 1 with all primary endpoints met and 74% of subjects showing protocol-defined immune responses, and the company is preparing a Phase 2 trial. Management believes current liquidity will fund operations for at least the next twelve months.
Anixa Biosciences (ANIX) reported continued operating losses but states it has sufficient liquidity for over 12 months. The company recorded net losses of $2.3 million for the three months and $8.3 million for the nine months ended July 31, 2025, with losses from operations of $2.4 million and $8.8 million, respectively. Cash, cash equivalents and short-term investments totaled $16,029,000 at July 31, 2025, down from approximately $19,924,000 at October 31, 2024, a reduction of about $3.9 million for the nine months. During the period the company raised approximately $1.924 million, net, from an at-the-market equity offering of 611,686 shares and issued options under its 2018 Share Incentive Plan (1,430,000 granted during the nine months). Stock-based compensation was $829,000 and $2,822,000 for the three- and nine-month periods, respectively. The company continues a 2,000 sq. ft. operating lease for its San Jose office with base rent of approximately $5,000 per month.